Frankfurt - Delayed Quote ? EUR BioSenic S.A. (BT1.F) Follow Compare 0.0055 -0.0024 (-30.38%) At close: October 25 at 8:00 AM GMT+2 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations BioSenic S.A. : Transparency notification received from ABO Infinium Americas OpCo LTD. REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, October 7, 2024, 7:00 CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received a transparency notification from ABO Infinium Americas OpCo LTD. The details of the transparency notification are set out below and the full text of the transparen GlobeNewswire ? 20 days ago BIOS.BR BIOS.PA BioSenic announces that it has started to look for new assets, the securing of its financing for the coming months by means of an amendment to its convertible bond contract, a change to the composition of its board of directors PRIVILEGED INFORMATION Biosenic and Global Tech Opportunities 15 ("GTO 15") have entered into an amendment to the convertible bonds ("CB") agreement securing a further EUR 1.5 million of the programme, including at least two tranches of EUR 0.2 million net each.Fran?ois Rieger and Véronique Pomi-Schneiter resign from their positions as CEO, chairman and executive director and non-executive director respectively, to focus on Medsenic. Finsys Management SRL, represented by its permanent representa GlobeNewswire ? 27 days ago BIOS.PA BIOS.BR BioSenic reports half year 2024 results REGULATED INFORMATIONThe interim financial report is prepared in accordance with article 13 of the Royal Decree on the obligations of issuers of financial instruments admitted to trading on a regulated market and can be accessed on the website of Biosenic in the section ‘Financial reports'. BioSenic publishes its interim financial report in English. A French translation of the report will also be made available. In the event of differences between the English and the French version of the report GlobeNewswire ? 27 days ago BIOS.BR BIOS.PA Véronique Pomi-Schneiter stands down as BioSenic's Deputy CEO PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, September 17, 2024 7.00pm CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases, today announces that Véronique Pomi-Schneiter resignes for personal reasons as Deputy CEO of BioSenic. Véronique Pomi-Schneiter will fully assist in the transition process and continue to serve as non-executive member of the board of directors of BioSenic, as well as an executive GlobeNewswire ? last month BIOS.PA BIOS.BR Medsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in relapsing-remitting multiple sclerosis INSIDE INFORMATION Medsenic's experimental drug, arsenic trioxide, can now be investigated for the treatment of multiple sclerosis through repeated cycles of administration by multiple routes, including intravenous, oral and other innovating routes of administration. Mont-Saint-Guibert, Belgium, August 14, 2024, 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases, today announces that the European Pate GlobeNewswire ? 2 months ago BIOS.PA BIOS.BR Medsenic/BioSenic patent granted in Japan for more protection of its therapeutic platform PRIVILEGED INFORMATION Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administration.Enriched IP portfolio protects arsenic trioxide (ATO) use combined with copper ions delivery, which has demonstrated increased therapeutic potential for indications ranging from immune to cancer and infectious diseases. Mont-Saint-Guibert, Belgium, 13 ao?t 2024, 6.00pm CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company GlobeNewswire ? 2 months ago BIOS.BR BIOS.PA BioSenic S.A. : Transparency notification received from Mr Fran?ois Rieger PRESS RELEASE – REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, July 19, 2024, 6pm CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received a transparency notification from Mr Fran?ois Rieger. The details of the transparency notification are set out below and the full text of the transpare GlobeNewswire ? 3 months ago BIOS.PA BIOS.BR BioSenic releases new in-depth analysis of its positive phase 2 clinical data for optimal administration scheme for its next late-stage trial of arsenic trioxide (ATO) targeting cGvHD Press Release The upcoming Phase 3 trial with ATO is more robust following a new post-hoc analysis. Mont-Saint-Guibert, Belgium, July 18, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases therapy, today announced the final results of a new, detailed post-hoc analysis of the Company's previous Phase 2 clinical trial of ATO for the first-line curative treatment of cGvHD. The analysis will be us GlobeNewswire ? 3 months ago BIOS.PA BIOS.BR BioSenic S.A. : Transparency notification received from Véronique Pomi PRESS RELEASE – REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, July 12, 2024, 6pm CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received a transparency notification from Ms Véronique Pomi. The notifications details can be found below and can be consulted on the website of BioSenic, unde GlobeNewswire ? 3 months ago BIOS.BR BIOS.PA Medsenic, subsidiary of BioSenic SA, extends key patent to the United States PRESS RELEASE – PRIVILEGED INFORMATION The developed Medsenic’s composition-of-matter patent family does cover the therapeutic use of arsenic salts and metal ions through various routes of administration.Medsenic’s enriched IP portfolio is aimed at protecting medications involving the combination of arsenic trioxide (ATO) and copper ions, which have demonstrated increased therapeutic potential for indications ranging from immune to cancer and to infectious diseases. Mont-Saint-Guibert, Belgium, GlobeNewswire ? 3 months ago BIOS.PA BIOS.BR Medsenic, BioSenic’s subsidiary, signed a new set of licensing and commercialization agreements with Phebra PTY Ltd. PRESS RELEASE – PRIVILEGED INFORMATION The adapted supply and commercialization conditions to better achieve the development of the first oral formulation of arsenic trioxide for the treatment of cGvHD should provide the best chances for final market access. Mont-Saint-Guibert, Belgium, July 2, 2024, 7.00am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS, GlobeNewswire ? 3 months ago BIOS.PA BIOS.BR BioSenic S.A. : Information on the total number of voting rights and shares PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, June 28, 2024, 7.00 am CET – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian law of 2 May 2007 on the publication of major sha GlobeNewswire ? 3 months ago BIOS.PA BIOS.BR BioSenic signs a new subscription agreement for a maximum of EUR 2.1M in convertible bonds PRESS RELEASE – PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, June 21, 2024 6.00pm CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces that it has signed a new subscription agreement for a maximum EUR 2.1 million convertible bonds ("CBs") facility, arranged by ABO Securities through its affiliated entity Global Tech Opportunities 15 ("GTO 15"). GTO 15 has committed to s GlobeNewswire ? 4 months ago BIOS.PA BIOS.BR The Enterprise Court of Nivelles approves the BioSenic restructuring plan PRESS RELEASE – PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, June 14, 2024 7.00am CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases, as well as cell repair, announces that it has received the homologation judgment for the restructuring plan filed with the Enterprise Court of Nivelles. This homologation judgment makes the plan binding on all deferred creditors, and the measures provided for therein w GlobeNewswire ? 4 months ago BIOS.BR BIOS.PA BioSenic to host Annual General Meeting on July 12, 2024 PRESS RELEASE – REGULATED INFORMATION Preliminary documents for the Annual General Meeting have been made available on company’s website Mont-Saint-Guibert, Belgium, June 12th, 2024 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, invites its shareholders and the holders of registered subscription rights and registered convertible bonds of the Company to the annual general meeting t GlobeNewswire ? 4 months ago BIOS.PA BIOS.BR BioSenic announces 2023 full year results PRESS RELEASE - REGULATED INFIRMATION BioSenic stopped the patient recruitment for its Phase 2b ALLOB trial in mid-2023. BioSenic has prepared a global restructuring plan covering the years 2024-2032 and will actively pursue follow-up actions. BioSenic expects to use the proceeds from anticipated future fundraising as a priority to progress its Phase 3 clinical trial in cGvHD. Mont-Saint-Guibert, Belgium, June 6, 2024, 9:00pm CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stag GlobeNewswire ? 4 months ago BIOS.PA BIOS.BR BioSenic S.A. : Positive vote of the majority of creditors in favor of the global restructuring plan of BioSenic covering the years 2024-2032, at the Enterprise Court of Nivelles PRESS RELEASE - PRIVILEGED INFORMATION After a recent circular consultation of the creditors, based on XX 83/23 of the Economic Law Code (ELC), the Enterprise Court of Nivelles registers today the positive votes of the majority of creditors on the Restructuration Plan presented by BioSenic and its restructuration practitioner, Ma?tre Yves Brulard. Mont-Saint-Guibert, Belgium, 27 May 2024, 5:00pm CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in seriou GlobeNewswire ? 4 months ago BIOS.PA BIOS.BR BioSenic provides First Quarter 2024 Business Update PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, May 24, 2024, 17.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces its business update for the first quarter, ended 31 March 2024. Key highlights In January 2024, BioSenic signed a new subscription agreement for a maximum EUR 1.2 million convertible bonds facility, arranged by ABO Securities through its GlobeNewswire ? 5 months ago BIOS.PA BIOS.BR BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles PRESS RELEASE - PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, 26 April 2024, 17:30 CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases, as part of the global restructuring plan announced on 11 April 2024, today announces the publication on its website of the following documentation : The restructuring plan covering the years 2024-2030 submitted to the Enterprise Court of Nivelles – accessible via the fo GlobeNewswire ? 5 months ago BIOS.BR BIOS.PA BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023 PRESS RELEASE - PRIVILEGED INFORMATION In view of the restructuring plan announced on April 11, 2024, BioSenic has decided to postpone the publication of its 2023 annual report as well as its annual general meeting of shareholders, so that the Enterprise Court of Nivelles can make a decision before the completion of the annual formalities. The Company believes that this postponement is preferable to ensure that the financial statements can be prepared on a going concern basis. Mont-Saint-Guibert GlobeNewswire ? 6 months ago BIOS.PA BIOS.BR Performance Overview Trailing total returns as of 10/25/2024, which may include dividends or other distributions. Benchmark is BEL 20 Return BT1.F BEL 20 YTD -93.13% +15.79% 1-Year -88.54% +28.52% 3-Year -99.61% +1.79%
